Gilead Sciences completes $4.3bn acquisition of CymaBay Therapeutics to enhance liver disease portfolio
Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a staggering $4.3 billion, a move that substantially strengthens Gilead’s position in the liver disease treatment landscape. The acquisition brings CymaBay’s leading investigational product, seladelpar, under Gilead’s expanding liver portfolio, marking a significant step forward in the […]
